Immunotechnology

Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity
pp. 241-251(11)
Authors: Yumitori S.; Nakanishi Y.; Ressing M.E.; Offringa R.; Toes R.E.M.; Ossendorp F.; de Jong J.H.; Brandt R.M.P.; Kast W.M.; Melief C.J.M.

An overview of the 1996 Keystone Meeting - Exploring and Exploiting Antibody and Ig Superfamily Combining Sites
pp. 253-260(8)
Authors: Huston J.S.; Haber E.

General features of antibody crystal structures.
pp. 261-261(1)
Authors: Davies D.R.; Chacko S.; Cohen G.H.

Structures of catalytic and anti-peptide antibody binding sites.
pp. 261-262(2)
Authors: Wilson I.A.; Stanfield R.L.; Haynes M.R.; Ghiara J.B.; Li H.; Heine A.; Stura E.A.

Oligosaccharide epitopes and antibody binding sites of Fab and single chain Fv molecules.
pp. 262-262(1)
Authors: Bundle D.R.; Brisson J.-R.; Cygler M.; MacKenzie C.R.; Narang S.A.; Young N.M.

The glycosylated adhesion domain of human CD2: glycan structure and significance for the interaction with CD58.
pp. 262-263(2)
Authors: Wagner G.; Choli J.S.; Jing L.; Smolyar A.; Reinherz E.; Knopper M.H.; Willis K.J.; Arulanandam A.R.N.; Wyss D.F.

Molecular basis of antigen mimicry by an anti-idiotopic antibody.
pp. 263-263(1)
Authors: Goldbaum F.A.; Fields B.A.; Fossati C.A.; Dall'Acqua W.; Poljak R.J.; Ysern X.; Mariuzza R.A.

Human antibody diversity
pp. 263-263(1)
Authors: Tomlinson I.M.; Walter G.; Jones P.T.; Dear P.H.; Sonnhammer E.L.L.; Winter G.

Engineering of anti-digoxin anybody combining sites
pp. 263-264(2)
Authors: Margolies M.N.; Short M.K.; Titlow C.C.; Jeffrey P.D.; Sheriff S.

Exploring and exploiting the anti-tumor monoclonal antibody BR96
pp. 264-264(1)
Authors: Sheriff S.; C. C.; Jeffrey P.D.; Bajorath J.; Yelton D.

Engineering the antibody combining site for high affinity binding
pp. 264-264(1)
Authors: Schier R.; McCall A.; Adams G.; Weiner L.M.; Marks J.D.

Using multiple loxP sites to access antibody heavy-light chain combinatorial diversity.
pp. 264-265(2)
Authors: Williams S.C.; Nissim A.; Hartley O.; Harrison J.L.; Griffiths A.D.; Winter G.

Generation of synthetic and lymphocyte-derived antibody libraries
pp. 265-265(1)
Authors: Little M.; Braunagel M.; Hayashi N.; Welschof M.; Dorsam H.; Dubel S.; Breitling F.; Kipriyanov S.; Tornesz P.

Studies of a phage-derived anti-CEA SCFV obtained from a combinatorial library
pp. 265-265(1)
Authors: Chester K.; Read D.; Robson L.; Verhaar M.; Keep P.; Nicholas W.; Casey J.; Pedley B.; Boden J.; Sharma S.; Hawkins R.; Michael P.; Melton R.; Springer C.; Begent R.

Radiochemistry in antibody targeting
pp. 265-266(2)
Author: Meares C.F.

Preclinical models for targeted therapy
pp. 266-266(1)
Author: Weiner L.M.

Redirected cellular cytotoxicity mediated by bispecific antibodies
pp. 266-266(1)
Authors: Segal D.M.; Titus J.A.; Sconocchia G.; Vance B.A.; Pericle F.; Kurucz I.; Jost C.R.; Bakacs T.

Optimization of catalysis and cytotoxicity
pp. 266-266(1)
Authors: Benkovic S.J.; Lee I.

Remodeling of a catalytic antibody through mutagenesis and selection
pp. 266-267(2)
Author: Hivert D.

Clinical imaging with a single chain Fv anti-CEA, potential for application to antibody directed enzyme prodrug therapy
pp. 267-267(1)
Authors: Begent R.H.J.; Chester K.A.; Napier M.N.; Casey J.L.; Green M.; Hope-Stone L.D.; Keep P.A.; Johnson C.J.; Hilson A.J.W.; Robson L.

Optimisation of the design of recombinant single-chain Fv fragments of antibody molecules
pp. 267-267(1)
Authors: George A.J.T.; Turner D.J.; Jamar F.; Ritter M.A.; Huston J.S.

High-affinity recombinant antibodies against neovasculature and extra-cellular matrix antigens
pp. 267-268(2)
Authors: Neri D.; Winter G.; Wyder L.; Klemenz R.; Neri G.; Pini A.; Botti R.; Neri P.; Castellani P.; Carnemolla B.; Zardi L.

Intracellular antibodies (intrabodies): development and gene therapy potential
pp. 268-268(1)
Author: Marasco W.A.

Idiotypes as vaccines for the treatment of B-cell malignancies
pp. 268-268(1)
Author: Kwak L.W.

B-cell superantigens: molecular, cellular and in vivo consequences
pp. 268-269(2)
Authors: Silverman G.J.; Nayak J.V.; Wagenknecht R.; Wamatz K.

Rational modification of antibodies and T-cell receptors.
pp. 269-269(1)
Authors: Rees A.R.; Searle S.J.; Henry A.H.; Smith L.; Sidiropoulou X.; Whitelegg N.; Ozeren M.

The folding pathway of antibodies: in vitro studies by NMR, engineering and selection for better folding.
pp. 269-269(1)
Authors: Freund C.; Honegger A.; Holak T.; Krebber C.; Spada S.; Pluckthun A.

Single-chain Fv immunotechnology.
pp. 269-270(2)
Authors: Huston J.S.; M.-S. T.; McCartney J.E.; Oppermann H.; Adams G.P.; Wolf E.J.; Weiner L.W.; Bookman M.A.; Houston L.L.; Stafford W.F.; George A.J.T.; Jamar F.; Heelan B.T.; Peters A.M.

Why are immune reactions to allografts so aggressive?
pp. 270-270(1)
Authors: Eisen H.N.; Sykulev Y.; Vturina I.; Xiangzhen Z.

Crystal structure of the V domain of a T cell antigen receptor.
pp. 270-270(1)
Authors: Fields B.A.; Ober B.; Malchiodi E.L.; Lebedeva M.I.; Braden B.; Ysern X.; Jin-Kyoo K.; Xuguang S.; Ward E.S.; Mariuzza R.A.

Utilization of the genetic and structural information on MHC molecules to study autoimmunity and alloreactivity.
pp. 270-271(2)
Author: Strominger J.L.

Molecular recognition of antigen involves CD4/MHC class II/TCR lattice formation on the surface of helper T lymphocytes.
pp. 271-271(1)
Authors: Sakihama T.; Smolyar A.; Reinherz E.L.

Isolated Ig superfamily domain units: MHC and beyond.
pp. 271-272(2)
Authors: Tykocinski M.L.; Brunschwig E.; Aoshuang C.; Fayen J.; Geho D.; Jui-Han H.; Levine E.; Meyerson H.; Srisuchart B.; Trefzer U.; Hsin-Min T.

Antibodies for immunosuppression and tolerance -- A war analogy.
pp. 272-272(1)
Authors: Waldmann H.; Cobbold S.P.

A novel strategy to reduce anti-idiotypic responses to campath-1.
pp. 272-273(2)
Authors: Gilliland L.; Isaacs J.; Frewin M.; Bloomer A.; Lesk A.; Hale G.; Waldmann H.

Immunoconjugates for therapy of carcinomas.
pp. 273-273(1)
Authors: Hellstrom K.E.; Firestone R.; Trail P.

The development of recombinant toxins for the treatment of cancer.
pp. 273-274(2)
Authors: Pastan I.; Lee H.P.; Brinkmann U.; Kreitman R.; FitzGerald D.

Single-chain immunotoxins for the treatment of carcinomas and hematologic malignancies.
pp. 274-274(1)
Author: Siegall C.B.

Transplantation without immunosuppression.
pp. 274-274(1)
Author: Faustman D.L.

Chimerism after organ transplantation -- the mechanism of graft acceptance
pp. 275-275(1)
Author: Starzl T.E.

Cellular basis of transplant-associated arteriosclerosis in genetically altered mice
pp. 275-275(1)
Authors: Chengwei S.; Wen-Sen L.; Qi H.; Newell J.B.; Haber E.

The complete nucleotide sequence of the human immunoglobulin D Segment Locus. [Abst. 100]
pp. 275-275(1)
Authors: Corbett S.J.; Tomlison I.M.; Buck D.; Sonnhammer E.L.L.

Characterization of anti-U1 RNA Fab isolated from bacteriophage display libraries
pp. 275-276(2)
Authors: Deutscher S.L.; Marchbank M.; Powers J.

Antigen-binding sites dominate the surface properties of antibodies
pp. 276-276(1)
Authors: Hansson U.-B.; Wingren C.; Andersson K.

Structure of a humanized anti-lysozyme FV domain. [Abst. 103]
pp. 276-276(1)
Authors: Holmes M.; Foote J.

Affinity maturation and structural analysis of a humanized antibody
pp. 276-276(1)
Authors: Hyo J.H.; Sung S.P.; Chun J.R.; Kyoung T.N.; Young H.K.; Moon H.H.

Design, expression and 3-D structure of bivalent single chain Ig-like molecules. [Abst. 105]
pp. 276-277(2)
Authors: Husdon P.; Atwell J.; Coia G.; Coleman P.; Dougan D.; Gruen C.; Iliades P.; Kortt A.; Lilley G.; Malby R.; McCoy A.; Pearce L.; Power B.; Tulloch P.

Characterisation of the binding sites of polyamine specific antibodies
pp. 277-277(1)
Authors: Johnston J.; Athwal D.; Beesley P.; Rider C.

The structure and antigen specificity of antibody binding sites can be influenced by clan-specific and family-specific amino acids in heavy chain frameworks 1 and 3. [Abst. 107]
pp. 277-277(1)
Authors: Kirkham P.M.; Elliott M.; Schroeder H.W.

Engineering scFvs and kinetic analysis of binding affinity on the BIAcore^TM
pp. 277-278(2)
Authors: Kortt A.A.; Gruen L.C.; Dougan D.A.; Malby R.L.; Hudson P.J.

Defective secretion of VH CDR2 mutant antibodies is characterized by increased association of the mutant heavy chains with molecular chaperones and is not a property of the light chain
pp. 278-278(1)
Authors: Martin T.M.; Wiens G.D.; Kowalczyk C.; Rittenberg M.B.

Comparison of the N10 structural, functional and energetic epitodes of staphhyococcal nuclease
pp. 278-278(1)
Authors: Perdue S.S.; Benjamin D.C.

A molecular model for an antibody that binds Le^x and sialyl Le^x
pp. 278-278(1)
Authors: Jianxia Q.; Quang D.; Nanping W.; Marcus D.M.; Padlan E.A.

Design of specifically-radiolabeled recombinant Fab: A search for Fab that bind the tumor antigens sialy-Lewis^x and Thomsen-Friedenreich glycoantigens from phage display libraries.
pp. 279-279(1)
Authors: Quinn T.P.; Karasseva N.; Glinsky G.; Deutscher S.; Peletskaya E.

Role of junctional diversity in anti-DNA antibodies.
pp. 279-279(1)
Authors: Radic M.Z.; Gottshall A.; Parmar M.; Seal S.

Polyreactive immunoglobulins display diversity in binding site topology.
pp. 279-279(1)
Authors: Ramsland P.A.; Guddat L.W.; Edmundson A.B.; Raison R.L.

Comparative protein modeling by satisfaction of spatial restraints.
pp. 279-280(2)
Author: Sali A.

Residues near the amino termini contribute to hapten recognition in a cloned anti-17-estradiol Fab fragment.
pp. 280-280(1)
Authors: Saviranta P.; Jauria P.; Pajunen M.; Lamminmaki U.; Lovgen T.

Bacterial expression of a human Fv fragment IgM with a novel antibody combining site.
pp. 280-280(1)
Authors: Shoebridge G.I.; Raison R.L.

Effects of mutations in the heavy chain CDR3 region on the affinity of an anti-PSA diabody.
pp. 280-281(2)
Authors: Shu L.; Smith R.; Abraham R.; Link J.; Venti C.; Darsley M.

Fv fragment crystal structures of the antibody B1-8 in unliganded form and with bound hapten NIP-CAP; analysis at 2 &unknown;9 resolution. [Abst. 119]
pp. 281-281(1)
Authors: Simon T.; Hirshberg M.; Winter G.; Henrick K.

Association of murine monoclonal antibody HyHEL-5 with lysozyme: biophysical characterization.
pp. 281-281(1)
Authors: Wibbenmeyer J.A.; Xavier K.A.; Shick K.A.; Wilson R.C.

Global changes in amide hydrogen exchange rates for a protein antigen in complex with three different antibodies.
pp. 281-282(2)
Authors: Williams D.C.; Benjamin D.C.; Poljak R.J.; Rule G.S.

Comparison of surface properties of human IgA, IgE, IgG and IgM antibodies with identical different specificities.
pp. 282-282(1)
Authors: Wingren C.; Hansson U.-B.

Testing of an experimentally supported peptid-Fab-model by site-directed mutagenesis.
pp. 282-282(1)
Authors: Winkler K.; Marx U.; Scholz C.; Kramer A.; Schneider-Mergener J.; Keitel T.; Hohne W.

Altered binding energetics of the M3 mutant of antibody D1.3 selected by phage display for enhanced binding to hen egg lysozyme.
pp. 282-283(2)
Authors: Wittrup K.D.; Mariuzza R.A.; Schwarz F.P.; Poljak R.J.

Isolation and characterization of human single chain Fv (scFv) against botulinum neurotoxin type A.
pp. 283-283(1)
Authors: Amersdorfer P.; Wong C.; Smith T.; Marks J.D.

Antibodies as modulators of protein activities -- implications for intravenous therapy.
pp. 283-283(1)
Authors: Andersson K.; Hansson U.-B.

Yeast surface display system for antibody engineering.
pp. 283-283(1)
Authors: Boder E.T.; Wittrup K.D.

A bacterial surface-expression system using OmpA fusion-proteins.
pp. 283-284(2)
Authors: Breit T.M.; Logtenberg T.

Selection of SCFV fragments against oxygen sensitive reduced flavin.
pp. 284-284(1)
Authors: Bruggerman Y.; Boogert A.; Schots A.; Hilhorst R.

Towards sequence-specific antibody proteases: a sensitive assay for peptide-bond hydrolysis.
pp. 284-284(1)
Authors: Bryant R.A.R.; Hansen D.E.

Isolation and partial characterization of human antibody fragments specific for group B Streptococcal (GBS) type III capsular polysaccharide isolated by phage display.
pp. 285-285(1)
Authors: David S.; de Kruif J.; Feldman R.G.; Rijkers G.T.; Zegers B.J.M.; Logtenberg T.

'Camelising' human VH domains for use as small recognition units. [Abst. 207]
pp. 285-285(1)
Authors: Davies J.; Riechmann L.

SCFV antibody fragments for breast tumor targeting.
pp. 285-285(1)
Authors: Finnem R.; Marks J.D.

scFv-kappa: A new single-chain antibody format showing increased expression levels in both procaryotic and eucaryotic systems.
pp. 286-286(1)
Authors: Fredholm L.; Persson M.A.A.

Humanization of murine 6G425: An anti-IL-8 monoclonal antibody which blocks binding of IL-8 to human neutrophils.
pp. 286-286(1)
Authors: Gonzalez T.N.; Leong S.; Kabakoff R.; Hebert C.; Presta L.

Studies on the interaction of the small organic pesticide molecule atrazine with single-chain antibody fragments
pp. 286-286(1)
Authors: Hayhurst A.; Strachan G.; Porter A.J.R.; Harris W.J.

Fine tuning of an antibody binding site by mutagenesis and phage display
pp. 286-287(2)
Authors: Hemminki A.; Niemi S.; Hakalahti L.; Soderlund H.; Takkinen K.

Isolation and characterization of antibody fragments directed to disease markers isolated from patient derived combinatorial libraries.
pp. 287-287(1)
Authors: Hoet R.M.A.; van den Hoogen F.H.J.; Raats J.H.H.; Litjens P.E.M.H.; de Wildt R.M.T.; van Venrooij W.J.

Interactions of recombinant Fab with nucleic acid: binding properties and role of heavy chain CDRS.
pp. 287-287(1)
Authors: Komissarov A.A.; Calcutt M.J.; Marchbank M.T.; Peletskaya E.N.; Deutscher S.L.

The analysis of anti-self and antimicrobial antibodies from a patient with SLE obtained from a combinatorial library.
pp. 287-288(2)
Authors: Kowal C.H.; Diamond B.

Construction of diabody phage display repertories for the selection of large numbers of bispecific antibody fragments.
pp. 288-288(1)
Authors: McGuinness B.T.; Walter G.; Fitzgerald K.; Duncan A.; Mahoney-Schuler P.; Mahoney W.; Hoogenboom H.

Generation of polyclonal and monoclonal catalytic sheep antibodies.
pp. 288-288(1)
Authors: Ozeren M.; Thomas N.R.; Stahl-Rees M.; Rees A.R.

Isolation of novel tumor antigens using antibody phage display.
pp. 288-289(2)
Authors: Pereira S.; Maruyama H.; Sivanandham M.; Wallack M.; Elder D.; Herlyn D.

Antibodies against crystals.
pp. 289-289(1)
Authors: Perl-Treves D.; Kam M.; Kessler N.; Addadi L.

Comparisons of expression in procaryotic and eucaryotic hosts of human recombinant Fab molecules.
pp. 289-289(1)
Authors: Persson M.A.A.; Samuelsson A.; Yari F.; Hinkula J.

In vitro selection of a high affinity anti-oestradiol antibody using a phage display human antibody library.
pp. 289-290(2)
Authors: Roberts A.; Pope A.R.; Pritchard K.; Williams A.; Johnson K.S.

Anti EGP-2 phage antibodies as a tool for identifying novel colon tumor antigens.
pp. 290-290(1)
Authors: Roovers R.C.; de Bruine A.; Kroesen B.-J.; Helfrich W.; de Leij L.; Arends J.-W.; Hoogenboom H.R.

Novel immunogen structures and immunization strategies induce antibodies to conserved epitopes of cannabiniods.
pp. 290-290(1)
Authors: Rosen S.M.; Hui R.; Vitone L.; Yeh S.; Cottell C.; Bender E.; Salamone S.J.

Engineering antibodies for tumor targeting using phage display.
pp. 290-291(2)
Authors: Schier R.; Adams G.; Marshall K.; McCall A.; Weiner L.; Bookman M.; Marks J.D.

Protein engineering: redesigning of the antibody combining site.
pp. 291-291(1)
Authors: Sidiropoulou X.; Rees A.R.

Rational mutation of a catalytic antibody.
pp. 291-291(1)
Authors: Smith L.C.; Rees A.R.

Generation of an estradiol specific anti-body by phage display.
pp. 291-292(2)
Authors: Smith R.G.; Abraham R.; Link J.; Venti C.; Darsley M.

Multicombinatorial libraries: new vectors and easy access to very large repertories.
pp. 292-292(1)
Authors: Sodoyer R.; Geoffroy F.; Bourchardon A.; Aujame L.

Selected light chains combine with a given heavy chain to confer anti-M or -N specificity.
pp. 292-292(1)
Authors: Spitalnik S.L.; Siegel D.L.; Czerwinski M.

The generation of polyurethane-specific catalytic antibodies.
pp. 292-292(1)
Authors: Stone M.O.; Brown W.E.

Isolation of high affinity and specificity testosterone binding antibodies from a phage display library.
pp. 292-293(2)
Authors: Takkinen K.; Hakalahti L.; Niemi S.; Soderlund H.; Hemminki A.

Properties of scFv proteins exhibiting specific binding to the plant enzyme enoyl acyl carrier portein reductase.
pp. 293-293(1)
Authors: Torrance L.; Zeigler A.; MacIntosh S.; Cowan G.; Mayo M.; Slabas T.

An expression system for catalytic anti-bodies: characterization and applications.
pp. 293-293(1)
Authors: Ulrich H.D.; Schultz P.G.

Characterization of ScFv antibodies against the human TSH-receptor derived from phage display libraries.
pp. 293-294(2)
Authors: van der Heijden J.W.H.; de Bruin T.W.A.; Glaudemans K.A.F.M.; de Kruif J.; Logtenberg T.

Isolation of human antibodies with sub-nanomolar affinities directly from a large non-immunized phage display library.
pp. 294-294(1)
Authors: Vaughan T.J.; Williams A.J.; Pritchard K.; Osbourn J.K.; Pope A.R.; Earnshaw J.C.; McCafferty J.; Wilton J.; Johnson K.S.

Isolation of cross-reactive anti-tetanus and anti-melittin antibodies by phage display.
pp. 294-294(1)
Authors: Vogel M.; Miescher S.; Zhang L.L.; Rudolf M.; Stadler B.M.

Characteristics of human anti-gal genes.
pp. 294-294(1)
Authors: Wang L.; Redic R.Z.; Siegel D.L.; Galili U.

Binding is not enough for catalysis.
pp. 294-295(2)
Authors: The Duc Hua; Weill M.; Souriau C.; Lazaro R.; Lefranc M.-P.

Molecular characterization of the antigen binding domain of a human natural anti-F(ab')₂ auto-antibody.
pp. 295-295(1)
Authors: Welschof M.; Little M.; Kipriyanov S.; Stanescu D.; Zewe M.; Hain C.; Dubel S.; Breitling F.; Opelz G.; Ternesz P.

Using multiple loxP sites to access antibody heaby-light chain combinatorial diversity.
pp. 295-295(1)
Authors: Williams S.C.; Nissim A.; Hartley O.; Harrison J.L.; Griffiths A.D.; Winter G.

In vivo selection of a lupus phage-display Fv library.
pp. 295-296(2)
Authors: Williams W.V.; Godillot A.P.; Srikantan V.; Satre M.; B. W.; Kieber-Emmons T.; Weiner D.B.

Cucumber mosaic cucumovirus antibodies from a synthetic phage display library.
pp. 296-296(1)
Authors: Ziegler A.; Torrance L.; MacIntosh S.M.; Cowan G.H.; Harper K.; Mayo M.A.

Influence of affinity, avidity and size on the tumor retention of anti-c-erB-2 single-chain Fv molecules. [Abst. 300]
pp. 296-296(1)
Authors: Adams G.P.; Schier R.; McCartney J.E.; McCall A.M.; Wolf E.J.; Mei-Sheng T.; Stafford W.F.; Houston L.L.; Huson J.S.; Marks J.D.; Weiner L.M.

Monoclonal antibodies to fimbriae inhibit proteusmirabilis attachment and invasion in vitro.
pp. 296-297(2)
Authors: Altman E.; Latta R.K.; Kok K.L.; Tolson D.L.; Harrison B.A.; Schur M.J.

Antigen binding peptides derived from long random peptide phage libraries mimic antibodies and can generate mimetopes.
pp. 297-297(1)
Authors: Alvarez V.L.; Carater J.M.; McConnell S.J.

Mammalian expression and characterization of a dimeric single chain antibody specific for integrin av3.
pp. 297-297(1)
Author: Beidler C.

Intracellular (PL) antibodies for virus immunotherapy in transgenic plants.
pp. 297-297(1)
Authors: Benvenuto E.; Tavladoraki P.

Eukaryotic expression vectors for the membrane display of single-chain antibodies: their use in the selection of transiently-transfected cells from total populations in culture.
pp. 297-298(2)
Authors: Chesnut J.D.; Russell M.; Chang M.-P.; Baytan A.R.; Maxwell I.H.; Hoeffler J.P.

Production and characterization of novel tetravalent bispecific antibodies.
pp. 298-298(1)
Authors: Coloma M.J.; Morrison S.L.

Generation of scFv immunotoxin molecules based on anti-B7.1/2 mabs for the treatment of Hodgkin's disease.
pp. 298-298(1)
Authors: de Boer M.; den Hartog M.; Balint R.; Vooys W.; de Gast B.

Leucine zipper dimerized bivalent and bispecific SCFV antibodies from a phage display library.
pp. 298-299(2)
Authors: de Kruif J.; Logtenberg T.

Generation of a humanized anti-CD40 mab for treatment of autoimmune diseases.
pp. 299-299(1)
Authors: den Hartog M.; Balint R.; Larrick J.; de Boer M.

Recombinant human antibodies against the Plasmodium falciparum glutamate rich protein.
pp. 299-299(1)
Authors: Dziegiel M.; Burgwald H.

Antimalarial antibodies produced by recombinant phage display.
pp. 299-300(2)
Authors: Foley M.; Shearing L.; Tilley L.; Anders R.

Preclinical development of huNR-LU-10, a humanized antibody for tumor targeting.
pp. 300-300(1)
Authors: Goshorn S.; Stone D.; Woodle D.; Graves S.; McIntyre R.; Axworthy D.; Bottino B.; Reno J.

Single chain Fv cytokine fusion proteins as vaccines for B cell lymphoma.
pp. 300-300(1)
Authors: Hakim I.; Levy S.; Levy R.

Macaque anti-human antibodies: analysis of the host response to a therapeutic humanized antibody.
pp. 300-301(2)
Authors: Hart T.K.; Ruggieri E.V.; Demuth S.G.; Davis C.B.; Silverman C.; Bugelski P.J.; Herzyk D.J.

In vivo expression of recombinant anti-tumor immunoglobulin-IL-2 fusion protein.
pp. 301-301(1)
Authors: Kashmiri S.V.S.; Prasad G.L.; Lee H.-S.; Iwahashi M.; Milenic D.; Schlom J.

A monoclonal antibody that blocks HIV-I gp120 glycoprotein binding to neurons.
pp. 301-301(1)
Authors: Latov N.; Lee G.

Genetically engineered lipid-tagged antibody; use in liposome-based fluoroimmunoassay.
pp. 301-302(2)
Authors: Laukkanen M.-L.; Keinanen K.

Selection of bivalent anti-PSA antibody clones from a phage display library.
pp. 302-302(1)
Authors: Link J.; Abraham R.; Smith R.G.; Venti C.; Darsley M.

Detecting novel cell surface antigens using phage antibody display.
pp. 302-302(1)
Authors: Logtenberg T.; van Vuurst A.R.; Cilenti L.; de kruif J.

Nuclear localization of autoantibodies: novel insights into protein translocation and cellular function.
pp. 302-303(2)
Authors: Madaio M.P.; Yanase K.; Foster M.H.; Smith R.M.; Kieber T.; Jarett E.L.; Fabbi M.; Puccetti A.

Monoclonal antibodies to a seminoma specific antigen.
pp. 303-303(1)
Authors: Marks A.; Sutherland R.; Law J.; Lei M.; Yeger H.; Bailey D.; Baumal R.

Bispecific antibody (ANTI-C3d/60.3), compensates, in vitro, for the elastase-mediated opsonin-receptor mismatch of cystic fibrosis.
pp. 303-303(1)
Authors: McCormick L.L.; Karulin A.Y.; Greenspan N.S.

Enhancing the tumor-specifity of human T cells by the expression of chimeric immunoglobulin/T cell receptor genes.
pp. 303-304(2)
Authors: Motmans K.; Raus J.; Vandevyver C.

Evaluation of different single chain constructs based on antineuroblastoma mab chCE7.
pp. 304-304(1)
Authors: Novak-Hofer I.; Carrel F.; Armstutz H.; Hasler P.; Schubiger P.A.

Database-supported antibody engineering.
pp. 304-304(1)
Authors: Ohage E.C.; Graml W.; Walter M.; Steipe B.

Inhibition of cyclin D1 oncogene with intracellular single chain antibodies.
pp. 304-305(2)
Authors: Poul M.-A.; Teyssier C.; Lefranc M.-P.

Antigen presentation of a T cell epitope inserted at different positions in an antibody heavy chain
pp. 305-305(1)
Authors: Sandlie I.; Bogen B.; Lunde E.

Recombinant TNF-B1 (Fv) fusion protein selectively kills LE^Y-antigen expressing TNF- sensitive human cancer cells
pp. 305-305(1)
Authors: Scherf U.; Benhar I.; Webber K.O.; Pastan I.; Brinkmann U.

Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens
pp. 305-305(1)
Authors: Solomon B.; Katsav-Gojanski T.; Hanan E.

Immunoglobulins and T cell receptors in inflammatory bowel disease
pp. 306-306(1)
Authors: Soprano A.; Koningsberger J.; Logtenberg T.

Intracellular targeting by anti-p21^ras scFv: A model for anti-tumor therapy
pp. 306-306(1)
Authors: Teillaud J.-L.; Delumeau I.; Schweighoffer F.; Cochet O.; Janicot M.; Kenigsberg M.; Tocque B.

Human antibodies specific for human TGF- derived from phage display libraries
pp. 306-306(1)
Authors: Tempest P.R.; Jackson R.H.; Williams A.J.; Green J.A.; Vaughan T.J.; Bacon L.; Johnson K.S.; Field R.; Wilton J.; Ruddock S.; Thompson J.

Evidence for distinct contributions of heavy and light chains to the restriction of antibody recognition of the human immunodeficiency virus type-1 principal neutralization deteminant
pp. 306-307(2)
Authors: Watkins B.A.; Davis A.E.; Fiorentini S.; Veronese F.; Reitz M.S.

Targeting adenovirus-mediated gene delivery with recombinant antibodies
pp. 307-307(1)
Authors: Watkins S.J.; Mesyanzhinov V.V.; Hawkins R.E.

The use of antibody fragments for the sensitive detection and removal of organic pollutants from the environment
pp. 307-307(1)
Authors: Williams S.; Porter A.J.; Learmonth D.; Grant S.D.; Strachan G.; Harris W.J.

Stabilization of a single-chain FV antibody by introduction of a disulfide bond
pp. 307-308(2)
Authors: Young N.M.; MacKenzie C.R.; Narang S.A.; Oomen R.P.; To R.; Baenziger J.E.

The role of IGG glycosylation in rheumatoid factor (RF) recognition
pp. 308-308(1)
Authors: Bonagura V.R.; Agostino N.; Thompson K.; Natvig J.B.; Wright A.; Morrison S.L.

Development of methodologies for the expression of soluble T-cell receptors (TCR)
pp. 308-308(1)
Authors: Harris W.J.; Molloy P.; Cunningham C.

Molecular analysis of the function of the human IGA FC domain
pp. 308-309(2)
Authors: Hexham J.M.; Carayannopoulos L.; Capra J.D.

The development of the interdomain interface as the recognition structure for FC receptor Ig interaction.
pp. 309-309(1)
Authors: Hogarth P.M.; Hulett M.D.; Rigby L.; Brinkworth R.; McKenzie I.

Expression of soluble T-cell receptor -- leucine zipper fusions.
pp. 309-309(1)
Authors: Jakobsen B.K.; Fu G.; Wilcox B.; Wyer J.R.; Vessey S.J.R.; O'Callaghan C.; Bell J.I.

Recombinant forms of a T-cell specific IGM.
pp. 309-309(1)
Authors: Johnson S.; Pfarr D.; Barren P.; Dillon S.; Couchenour D.; Goldman D.; Sheau-Chiann W.; Brown S.; Thompson J.; Koenig S.

Induction of anti-carbohydrate immune responses by carbohydrate mimicking peptides.
pp. 309-310(2)
Authors: Kieber-Emmons T.; Blaszczyk-Thurin M.; Murali R.; Agadjanyan M.; Carey L.A.; Ping L.; Steplewski Z.; Bin W.; Weiner D.B.; Westerink M.A.J.

T cell receptor interactions with photoreactive H-2KD^d peptide derivative complexes.
pp. 310-310(1)
Authors: Luescher I.F.; Kessler B.; Jongeneel C.V.; Gachelin G.; Bentley G.A.; Malissen B.

Recombinant human HLA-DR1 class II MHC molecules as biologically active covalently-linked heterotrimers of antigenic peptide, beta chain and alpha chain.
pp. 310-310(1)
Authors: Mage M.; Xiaojie Z.; Sadegh-Nasseri S.

Display OFT-cell receptors on filamentous phage.
pp. 310-311(2)
Authors: Nielsen U.B.; Hufton S.; Stam K.; Willemsen R.; Bolhuis R.; Hoogenboom H.R.

Role of chain pairing and peptide occupancy for the production of functional soluble IA MHC class II molecules.
pp. 311-311(1)
Authors: Scott C.; Garcia C.; Carbone F.; Wilson I.; Teyton L.

C-CAM mediates adhesion through a homophilic domain 1/domain 1 interaction in transfected CHO cells.
pp. 311-311(1)
Authors: Wilkstrom K.; Obrink B.

R/K residues located in the middle positions of peptide where side chains protrude towards the solvent may directly prevent HLA-A11 specific antibody, AUF5.13, from binding to the complexes.
pp. 311-312(2)
Authors: Zhang Q.-J.; Masucci M.G.

An antibody against a specific peptide/MHC class I complex.
pp. 312-312(1)
Authors: Andersen P.S.; Hansen A.S.; Hansen B.E.; Fugger L.; Engberg J.; Buus S.

Binary toxins for targeting cancer cells.
pp. 312-312(1)
Authors: Raso V.; Sheldon K.; Deldon D.

Implications and applications of monogamous and crosslinking multivalent antibody binding.
pp. 312-312(1)
Authors: Greenspan N.S.; Cooper L.J.N.; McCormick L.L.; Karulin A.Y.; Feeney A.J.; Charoenvit Y.; Hoffman S.L.

Single-chain immunofusions engineered with human RNases.
pp. 313-313(1)
Authors: Newton D.L.; Rybak S.M.

High affinity antibodies against 3-FL (Le^x, CD15) from a phage display library.
pp. 313-313(1)
Authors: Marcus D.M.; Weng N.; Hasegawa A.; Dinh Q.

Design, expression, structure and immunochemistry of bivalent single chain Ig-like molecules.
pp. 313-314(2)
Authors: Hudson P.; Atwell J.; Coia G.; Colman P.; Dougan D.; Gruen C.; Iliades P.; Kortt A.; Lilley G.; Malby R.; McCoy A.; Pearce L.; Power B.; Tulloch P.